Fast access to useful resources and the narrative report of this mapping site.
The following resources provide additional insight and information on the global landscape, including current challenges and opportunities, confronting TB care and IQA-SLD supply and access.
Download the narrative analysis of this initiative's findings. This data is current as of September 2017.
The TB Drug Access Atlas is a data-driven tool built with the goal to help inform decision-making, reduce programmatic redundancy where appropriate, take advantage of shared strengths, and address clear gaps in the areas of intervention where needed. Learn more about the Atlas, and view a tutorial for how to use the site.Learn More
The research team used a combination of publicly available information and reports to populate project drivers, regions of work, project budgets, partner organizations, project contacts, milestone dates, and activity timelines. Over the course of the next two months, all project leads were contacted requesting their participation in the mapping exercise. Each contact who agreed to participate was first asked to fill out a Qualtrics survey intended to summarize project goals, approximate budget range, primary funders, activity timeline, partner organizations, regions where the project is working, and other projects they might be aware of working in a similar space. Participants were also asked to participate in a 30-45 minute telephone interview with a member of the research team. Interviews were attended by at least two members of the research team, one leading the interview and the other recording details of the interview.Learn More
The following resources provide additional insight and information on the global landscape, including current challenges and opportunities, confronting TB care and IQA-SLD supply and access.View All
The Lilly Global Health Partnership is ambitiously working to increase access to quality health care and to improve long-term health for millions of people worldwide.
Through investments in people, medicines and health systems, Lilly aims to reach 30 million people in resource-limited settings annually by 2030. The cornerstone of this goal - known as Lilly 30x30 - is a new five-year, $90 million investment in the Lilly Global Health Partnership, which will improve access to treatment for diabetes, cancer and tuberculosis.
Have a question or feedback? Please contact us and we'll get right back in touch.Contact Us